Rodano, Italy – January 26^th, 2018 – Between 2016 and 2017, Olon SpA, European leader of API manufacturing, invested more than 10 million € to expand APIs manufacturing lines in Settimo Torinese facility, which is the leading-edge plant for development and production of APIs and advanced intermediates through microbial fermentation technology. This investment allowed Olon to increase production capacity of APIs up to approx. 1500 kg/year, with different batch sizes up to 30 kg/batch.

This investment included the empowering of DSP (Downstream Process), involving the installation of four (4) different full automated chromatographic columns, besides the installation of six (6) new reactors and a new TFF (Tangential Flow Filtration) unit. Additionally, to isolate lyophilised products in GMP conditions, a new freeze dryer was installed. Utilities and warehouses was empowered with a cold room as well, in order to guarantee the cold chain within the whole process

The investment involved not only the DSP but also the fermentation area. In fact, a fundamental step to increase the yearly capability was the installation of new fermenters equipped with the standard state of art automation system.

The new APIs productive line is GMP compliance and validated. It is part of an ongoing strategic investment campaign in APIs manufacturing, which involves all Olon sites.

For several years Olon Settimo Torinese plant has been a partner in supplying thermal energy to the urban community heating network of Settimo Torinese which provides citizens, companies and institutions, such as Hospital, Commercial Centers and other industries of the area with heat and sanitary water.

In reference to Olon core business in producing Pharmaceutical products, energy consumption efficiency has been highly regarded by developing the best service integration with the urban community context, especially in Olon Settimo Torinese plant.

In particular, this year Olon has established an agreement with the multinational corporation ENGIE, which took over the acquisition and the management of the local urban heating network.

This new partnership will evolve into the installation of a new production unit in the plant in order to accomplish better use of thermal energy requests by both, the company and the community around.

OLON SPA (P&R Group) ACQUIRES RICERCA BIOSCIENCES CHEMICAL DIVISION IN OHIO (USA)

Acquisition strengthens service offering of global CDMO and Generics provider for research and manufacturing

Milan (Italy) – June 9, 2017 Olon S.p.A., a world leading Active Pharmaceutical Ingredients (API) contract development and manufacturing organization (CDMO) and Generics supplier, announced today the acquisition of Ricerca Biosciences’ Chemical Division of the contract research (CRO) and CDMO based in Concord, Ohio, USA. This acquisition strengthens the service offering of Olon for the pharmaceutical and biotech industry, and to benefits the Ricerca Biosciences customer base by providing large scale manufacturing capabilities in Europe.

Paolo Tubertini, CEO of Olon, commented, "By acquiring a research and manufacturing base in the US, Olon will have the opportunity to accelerate growth by adding new CDMO projects and to develop new Generic products for the American market." Luca Mantovani, OLON Managing Board member, added, "We are delighted to add Ricerca Biosciences to Olon Group, as this strategic step will broaden our contract research and manufacturing services for all our global customers". No financial details were disclosed.

About Ricerca
Ricerca Biosciences is a US-based CRO supporting the development and manufacture of APIs and performance materials in support clinical supply, market development and commercial distribution.  Ricerca’s extensive process/synthetic chemistry, analytical chemistry and engineering expertise provides a synergy that excels at first-time scale-ups and subsequent development of safe, reliable, robust and cost effective manufacturing processes.    Meeting client needs has been the foundation of Ricerca’s business philosophy and is second only to its commitment to safety and regulatory compliance. www.ricerca.com